TOP STORIES

• BUSINESS Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
  October 11, 2016

• ACADEMIA Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
  October 7, 2016

• REGULATORY Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
  October 6, 2016

• REGULATORY Kaketsuken Faces Another Penalty over Encephalitis Vaccine Manufacturing
  October 5, 2016

• REGULATORY MHLW, PMDA Set Up “Preparatory Offices” to Plan Future Support System for Startups
  October 5, 2016

• REGULATORY Bayer Launches Recall of Hemophilia Med Kogenate over Potency Loss
  October 4, 2016

• BUSINESS Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
  October 3, 2016

• REGULATORY MHLW Says It Will Compile “Optimal Use Guidelines” for Keytruda Too
  October 3, 2016

• BUSINESS Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
  September 30, 2016

• REGULATORY Drug Costs Biggest Driver of Healthcare Spending Surge: Chuikyo JMA Rep
  September 29, 2016

• BUSINESS Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
  September 28, 2016

• REGULATORY Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
  September 27, 2016

• TRENDS Japan’s Established Drug Market Shines as Renewed Opportunity for Foreign Generic Firms
  September 26, 2016

• REGULATORY Pharma, Govt Hold 1st Kanmin Taiwa Working Group Talks; Industry Calls for Trial-Friendly Environment, Discussions on Pricing
  September 23, 2016

• BUSINESS Nichi-Iko to Set up Biosimilar Dept. in October to Push Remicade Follow-On
  September 21, 2016

• BUSINESS Eisai Looks to Achieve CAGR of 55% for Fycompa with Add’l Indications
  September 20, 2016

• REGULATORY As Personal Info Law Amendment Looms, Govt Official Tells Drug Makers to Review Info in Hand
  September 16, 2016

• REGULATORY Industry Chiefs, Chuikyo Panelists Trade Barbs over Market Expansion on Add’l Indications
  September 15, 2016

• BUSINESS Novartis Eager to See More 1st Approvals in Japan despite Pricing Headache
  September 14, 2016

• REGULATORY Blue Book “Will Be Used as Reference When Selecting Generics”: Panel Chair
  September 14, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 147
• 148
• 149
• 150
• 151
• 152
• 153
• 154
• 155
• …
• Next ›
• 最終 »